Last update 21 Nov 2024

Interferon alpha-2b (Beijing Kawin Technology)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Interferons

Synonyms

Interferon alpha2b vaginal effervescent tablet Beijing Kawin technology, Recombinant human interferon alpha2b injection Beijing Kawin technology, Recombinant human interferon α2b(Beijing Kawin Technology)

+ [3]

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [7]

Active Indication

Kidney NeoplasmsHairy Cell LeukemiaPhiladelphia chromosome positive chronic myelogenous leukemia+ [12]

Inactive Indication

COVID-19

Originator Organization

Beijing Kawin Technology Share-Holding Co., Ltd.

Active Organization

Beijing Kawin Technology Share-Holding Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (15 Dec 2012),

Uterine Diseases

Regulation-

Gene Sequence

Sequence Code 167544

Clinical Trials associated with Interferon alpha-2b (Beijing Kawin Technology)

CTR20233836 / Not yet recruitingPhase 2

评价人干扰素α2b喷雾剂治疗儿童疱疹性咽峡炎患儿的有效性和安全性的多中心、随机、双盲、安慰剂对照的II期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of human interferon α2b spray in the treatment of herpetic pharyngitis in children

主要目的：评价人干扰素α2b喷雾剂治疗儿童疱疹性咽峡炎的有效性。次要目的：评价人干扰素α2b喷雾剂治疗儿童疱疹性咽峡炎的安全性；探索人干扰素α2b喷雾剂治疗儿童疱疹性咽峡炎的有效剂量。

[Translation]

Primary purpose: To evaluate the effectiveness of human interferon α2b spray in the treatment of herpetic pharyngitis in children. Secondary purpose: To evaluate the safety of human interferon α2b spray in the treatment of herpetic pharyngitis in children; To explore the effective dose of human interferon α2b spray in the treatment of herpetic pharyngitis in children.

Start Date-

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

CTR20241695 / RecruitingPhase 2

随机、双盲、安慰剂对照评价人干扰素α2b阴道泡腾片辅助治疗阴道/宫颈尖锐湿疣有效性和安全性的II期临床试验

[Translation] A randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of human interferon α2b vaginal effervescent tablets in the adjuvant treatment of vaginal/cervical condyloma acuminatum

主要目的：评价人干扰素α2b阴道泡腾片辅助治疗女性阴道/宫颈尖锐湿疣的有效性；次要目的：评价人干扰素α2b阴道泡腾片辅助治疗女性阴道/宫颈尖锐湿疣的安全性。

[Translation]

Primary purpose: To evaluate the effectiveness of human interferon α2b vaginal effervescent tablets in the adjuvant treatment of female vaginal/cervical condyloma acuminatum; Secondary purpose: To evaluate the safety of human interferon α2b vaginal effervescent tablets in the adjuvant treatment of female vaginal/cervical condyloma acuminatum.

Start Date17 Jun 2024

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

CTR20223324 / RecruitingPhase 1

一项在中国健康成年受试者中评价人干扰素α2b喷雾剂单次给药的安全性、耐受性、药代动力学和药效动力学的单中心、开放标签、剂量递增I期临床研究

[Translation] A single-center, open-label, dose-escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of human interferon α2b spray in healthy Chinese adult subjects

主要目的：1）评价人干扰素α2b喷雾剂在中国健康成年受试者中单次用药的安全性和耐受性。次要目的：1）评价人干扰素α2b喷雾剂在中国健康成年受试者中单次用药的药代动力学（PK）特征。2）评价人干扰素α2b喷雾剂在中国健康成年受试者中单次用药的药效动力学（PD）。3）评价人干扰素α2b喷雾剂的免疫原性。

[Translation]

Primary objectives: 1) To evaluate the safety and tolerability of a single dose of human interferon α2b spray in healthy Chinese adult subjects. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of a single dose of human interferon α2b spray in healthy Chinese adult subjects. 2) To evaluate the pharmacodynamics (PD) of a single dose of human interferon α2b spray in healthy Chinese adult subjects. 3) To evaluate the immunogenicity of human interferon α2b spray.

Start Date06 Jan 2023

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

100 Clinical Results associated with Interferon alpha-2b (Beijing Kawin Technology)

100 Translational Medicine associated with Interferon alpha-2b (Beijing Kawin Technology)

100 Patents (Medical) associated with Interferon alpha-2b (Beijing Kawin Technology)

Literatures (Medical) associated with Interferon alpha-2b (Beijing Kawin Technology)

Clinical, Cosmetic and Investigational Dermatology

Adjuvant Therapy in Acral Melanoma: A Systematic Review

Review

Author: Liu, Mingjuan ; Li, Jun ; Zheng, Heyi ; Zhu, Zhou ; Zhang, Hanlin

BackgroundAcral melanoma presents distinct biological characteristics compared to cutaneous melanoma. While adjuvant therapeutic strategies for high-risk resected acral melanoma closely resemble those for cutaneous melanoma, the evidence supporting the clinical application of adjuvant therapy for acral melanoma remains inadequate. Our aim was to systematically analyze the efficacy and safety profile of adjuvant therapy in acral melanoma.MethodsThis systematic review adhered to a pre-registered protocol. We comprehensively searched four electronic databases and reference lists of included articles to identify eligible studies. The primary outcome was therapeutic efficacy, and the secondary outcome was adverse events (AEs).ResultsThis systematic review included 11 studies with 758 acral melanoma patients undergoing adjuvant therapy. High-dose interferon α-2b (IFN) regimens showed no significant difference in recurrence-free survival (RFS), though the longer regimen was linked to increased hepatotoxicity. Adjuvant anti-PD-1 therapy demonstrated varying efficacy, with improved RFS in patients who experienced immune-related AEs. Targeted therapy with dabrafenib plus trametinib achieved high 12-month RFS in patients with BRAF-mutated acral melanoma. Comparative studies suggested that adjuvant anti-PD-1 therapy is similarly effective to IFN in prolonging survival for high-risk acral melanoma patients. Additionally, prior treatment with pegylated IFN enhanced RFS in patients receiving adjuvant pembrolizumab.ConclusionHigh-dose IFN was widely used as adjuvant therapy for acral melanoma, but serious AEs prompted the search for alternatives. Adjuvant anti-PD-1 therapy shows promise, though it may be less effective than in non-acral melanoma. Further prospective studies are needed to determine the optimal adjuvant treatment for acral melanoma.

Frontiers in Cellular and Infection Microbiology

A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study

Article

Author: Chen, Tianyan ; Zheng, Jie ; Shi, Lei ; He, Yingli ; Zhu, Yage ; Yan, Lanzhi ; Zhong, Wenting

Background and aimsLimited data have been reported on achieving functional cure using pegylated interferon (Peg-IFN) alpha-2b treatment for postpartum hepatitis B e antigen (HBeAg)-negative women with chronic hepatitis B virus (HBV) infection. This study was to assess the effectiveness and safety of Peg-IFN alpha-2b in HBV postpartum women without HBeAg and identify factors linked to the functional cure.MethodsA total of 150 HBeAg-negative postpartum women were retrospectively recruited.47 patients received Peg-IFN alpha-2b [Peg-IFN(+) group] and 103 patients did not [Peg-IFN(-) group]. Propensity score matching (PSM) was used to adjust the baseline imbalance between the two groups. The patients were followed for at least 48 weeks. The primary endpoints were hepatitis B surface antigen(HBsAg) loss and HBsAg seroconversion at 48 weeks. Logistic regression analysis was used to assess factors associated with HBsAg loss at 48 weeks.ResultsAt week 48,the HBsAg loss and seroconversion rate in Peg-IFN(+) group were 51.06%(24/47) and 40.43%(19/47), respectively. Even after PSM, Peg-IFN(+) group still showed higher HBsAg loss rate (50.00% vs 7.14%,p<0.001) and higher HBsAg seroconversion rate (38.10% vs 2.38%,p<0.001). Baseline HBsAg levels (Odds Ratio [OR]: 0.051, 95% Confidence Interval [CI]: 0.003-0.273, P=0.010), HBsAg at week 24 (OR:0.214, 95%CI:0.033-0.616, P=0.022), HBsAg decline at week 24 (OR:4.682, 95%CI: 1.624-30.198, P=0.022) and postpartum flare (OR:21.181, 95%CI:1.872-633.801, P=0.030) were significantly associated with HBsAg loss at week 48 after Peg-IFN alpha-2b therapy. Furthermore, the receiver operating characteristic curve (ROC) showed that the use of baseline HBsAg<182 IU/mL, HBsAg at week24 < 4 IU/mL and HBsAg decline at week24>12IU/mL were good predictors of HBsAg loss. No serious adverse events were reported.ConclusionPeg-IFN alpha-2b treatment could achieve a high rate of HBsAg loss and seroconversion in HBeAg-negative postpartum women with reliable safety, particularly for patients experience postpartum flare and have low baseline HBsAg levels.

100 Deals associated with Interferon alpha-2b (Beijing Kawin Technology)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Neoplasms	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	20 Sep 2015
Hairy Cell Leukemia	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	21 Aug 2015
Philadelphia chromosome positive chronic myelogenous leukemia	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	18 Aug 2015
Condylomata Acuminata	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	15 Aug 2015
Hepatitis C	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	15 Aug 2015
Basal Cell Carcinoma	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	14 Aug 2015
Ovarian Epithelial Carcinoma	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	13 Aug 2015
Melanoma	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	12 Aug 2015
Kaposi Sarcoma	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	11 Aug 2015
Chickenpox	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	09 Aug 2015
Multiple Myeloma	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	09 Aug 2015
Hepatitis B	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	06 Aug 2015
Uterine Diseases	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	15 Dec 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpangina	Phase 2	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	27 Nov 2023
Herpes Genitalis	IND Approval	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	19 Mar 2024
COVID-19	Discovery	CN	Beijing Kawin Technology Share-Holding Co., Ltd.	07 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis